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ABSTRACT
DNA double-strand breaks (DSBs) are toxic lesions,
which if improperly repaired can result in cell death
or genomic instability. DSB repair is usually facili-
tated by the classical non-homologous end joining
(C-NHEJ), or homologous recombination (HR) path-
ways. However, a mutagenic alternative NHEJ path-
way, microhomology-mediated end joining (MMEJ),
can also be deployed. While MMEJ is suppressed by
C-NHEJ, the relationship between HR and MMEJ is
less clear. Here, we describe a role for HR genes
in suppressing MMEJ in human cells. By moni-
toring DSB mis-repair using a sensitive HPRT as-
say, we found that depletion of HR proteins, includ-
ing BRCA2, BRCA1 or RPA, resulted in a distinct
mutational signature associated with significant in-
creases in break-induced mutation frequencies, dele-
tion lengths and the annealing of short regions of
microhomology (2–6 bp) across the break-site. This
signature was dependent on CtIP, MRE11, POLQ and
PARP, and thus indicative of MMEJ. In contrast to
CtIP or MRE11, depletion of BRCA1 resulted in in-
creased partial resection and MMEJ, thus revealing
a functional distinction between these early acting
HR factors. Together these findings indicate that HR
factors suppress mutagenic MMEJ following DSB re-
section.
INTRODUCTION
DNA double strand breaks (DSBs) are deleterious lesions
that if left unrepaired can lead to cell death, while if mis-
repaired can give rise to genomic instability, thus lead-
ing to tumorigenesis (1). To survive such lesions and pre-
serve genome integrity, cells possess two main evolution-
arily conserved DSB repair mechanisms, namely homolo-
gous recombination (HR), and non-homologous end join-
ing (NHEJ) (2). Other repair pathways generally referred to
as alternative non-homologous end joining pathways (Alt-
NHEJ) (3–5), have been of recent interest. A subset of these
repair mechanisms relies on regions of microhomology on
either side of the break, which anneal following limited re-
section in a process called microhomology-mediated end
joining (MMEJ) (6–8).
HR is an error-free DSB repair pathway that proceeds
through three phases. In mammalian cells the presynap-
tic phase is triggered by a two-step 5′ to 3′ end resec-
tion that produces 3′ single-stranded DNA (ssDNA) over-
hangs. Resection is initiated by the endonucleolytic activity
of the MRE11-RAD50-NBS1 (MRN) complex and the C-
terminal binding protein interacting protein (CtIP), which
exposes short ssDNA tails (9,10). These become substrates
for the extensive resection mediators, Exo1, DNA2 and
BLM (11,12). BRCA1 also facilitates the initial resection
step of HR (13,14) in conjunction withMRN (15) and CtIP
(15,16), where it accelerates the DSB resection rate (17).
The exposed ssDNA is initially protected by Replication
Protein A (RPA) (18), which is then displaced by RAD51,
following its recruitment by BRCA2, to form a nucleopro-
tein filament (19). The RAD51 nucleofilament promotes
strand invasion of the undamaged sister chromatid, which
is used as a repair template, resulting in a displacement
loop (D-loop). During the synaptic phase of HR, the 3′ end
is extended by DNA replication, which can subsequently
proceed through a number of sub-pathways. During DSB
repair, second end capture and annealing results in dou-
ble Holliday junction (HJ) formation. In the post-synaptic
phase of HR, HJ structures can be resolved with or without
crossovers, or dissolved, thus preventing crossovers (20,21).
Alternatively, during synthesis-dependent strand annealing
(SDSA) (22), the invading and extended strand is expelled
from the D-loop to anneal to the second end which, follow-
ing gap filling and ligation, results in error-free repair (23).
Classical NHEJ (C-NHEJ) is triggered by recognition
and protection of DNA ends by the Ku70/Ku80 het-
erodimer, which forms a ring that encircles duplex DNA.
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This protects ends from resection and creates a platform
to recruit the DNA-PK catalytic subunit (DNA-PKcs)
(24,25). Broken ends are then trimmed by Artemis and
ligated by DNA Ligase 4 (Lig 4), X-ray repair cross-
complementing protein 4 (XRCC4) complex, and XRCC4-
like factor (XLF), depending on the nature of the damage
(25–27). Although end-protection by Ku in this pathway
minimizes resection, thus promoting error-free end joining,
this pathway is widely referred to as error-prone as it lig-
ates the ends in a homology-independent fashion poten-
tially leading to small insertions, and/or deletions (indels)
at the DSB sites. From a genome-wide perspective, however,
C-NHEJ is not as threatening as alternative NHEJ (Alt-
NHEJ) pathways for mammalian genome stability (24) and
is even considered as a guardian of genome stability (28).
Alt-NHEJ refers to DSB end joining pathways that are
independent of the C-NHEJ factors Ku70/Ku80, DNA-
PKcs and DNA Lig4. Unlike C-NHEJ, these pathways are
highly mutagenic, always associated with indels and com-
monly lead to chromosomal rearrangements. Importantly,
a sub pathway of Alt-NHEJ events termed microhomology
mediated end joining (MMEJ) rejoins the ends by base pair-
ing between microhomologous sequences. MMEJ is me-
diated via CtIP, MRN complex, Poly [ADP-ribose] poly-
merases1 (PARP-1) and DNA ligase 3 (Lig 3) (29,30). In
mammalian cells, PARP-1, a key component of the MMEJ
pathway (31), initially competes with Ku heterodimer for
binding to DNA ends resulting in PAR formation (32,33).
This in turn promotes MRE11 recruitment and the initia-
tion of resection by MRN complex and CtIP (34). Subse-
quently, DNA end ligation is mediated through DNA Lig 3
(7,35). Further, recent studies have identified a low fidelity
DNA polymerase  (Pol also known as POLQ) (36) as an
important MMEJ factor in mammalian cells. POLQ is re-
cruited toDSB ends by PARP-1where it facilitates end join-
ing and microhomology annealing (37). While absent from
yeast, the role for POLQ inMMEJ appears to be conserved
in flies, worms, mice and humans (38). MMEJ generates
deletions and translocations at the break points and thus
is highly mutagenic (39). However, there are other types of
Alt-NHEJ events that do not rely on suchmicrohomologies.
The ligation step in these pathways is facilitated through
DNA ligase 1(Lig1) (6).
Impairment of a DSB repair pathway is a common fea-
ture in human cancers, rendering their survival highly de-
pendent on secondary DSB repair pathways (40). There-
fore, studies of the relationships between different DSB re-
pair machineries are of interest as they can provide insight
into how to target these defects for cancer therapy purposes.
In this regard, HR has an inhibitory impact on C-NHEJ
via initiation of resection (41). Conversely, C-NHEJ sup-
presses HR and Alt-NHEJ by Ku binding and preventing
the resection initiation (42,43). However, the exact nature
of the interplay between HR and Alt-NHEJ in human cells
still remains elusive. A recent study in MEFs (Mouse Em-
bryonic Fibroblast Cells) found elevated levels of PARP-1-
dependent translocations following loss of the HR factor
RAD54 (44).Moreover, a study in Saccharomyces cerevisiae
(S. cerevisiae) showed that RPA impairs MMEJ by remov-
ing the secondary structures of ssDNA, which facilitates
RAD51 filament assembly leading to HR and thereby sup-
pression of annealing of the terminalmicrohomologies (45).
On the other hand, two recent studies in mammalian cells
suggested that POLQ-mediated Alt-NHEJ suppresses HR
repair mechanisms (46,47). A role for BRCA1 in promoting
NHEJ fidelity has been proposed (48). However, studies in
MEFs have also shown that BRCA1 promotes Alt-NHEJ
at uncapped telomeres (49).
Here, we have investigated the relationship between HR
and MMEJ repair of DSBs. We have used a highly sensi-
tive HPRT-based assay (50,51) together with other GFP-
based reporter assays (52–54) to characterize DSB mis-
repair events observed following depletion or inhibition of
HR and NHEJ factors. Following both physical and ge-
netic analyses, we have established a role for HR factors
in suppressing MMEJ at break point junctions. Further,
our data suggest the existence of POLQ-dependent and
POLQ-independent MMEJ pathways, both of which are
suppressed by RPA. Last, we define a role for BRCA1 in
functioning downstream of CtIP and MRE11 to promote
resection, thereby preserving genome integrity by counter-
acting MMEJ.
MATERIALS AND METHODS
Cell culture
HT1080 (human fibrosarcoma, HPRT assay), U2OS (hu-
man osteosarcoma, GFP-based HR reporter (52)), and
H1299 (human non-small cell lung carcinoma, GFP-based
C-NHEJ reporter (54)) cells were cultured as described pre-
viously (51,55). C-NHEJ reporter cells were a kind gift from
Atsushi Shibata and Takashi Kohno. MMEJ reporter cells
(U2OS with integrated EJ2-GFP reporter) were a kind gift
from Jeremy Stark (53) and were grown in high glucose
DMEM supplemented with L-glutamine, 10% fetal bovine
serum, and 1% Pen/Strep solution (10 000 U/ml penicillin,
10 000 mg/ml streptomycin), including 8 mg/ml plasmocin
and 2 mg/ml puromycin.
HAT to select for HPRT gain of function
HAT selection was carried out by adding 1× HAT supple-
ment (Invitrogen) directly to the DMEM medium for 10
days before the I-SceI transfection.
6-TG to select for HPRT loss of function
6-TG selective medium was made by making up 1000 × 6-
TG of 15 mg/ml by dissolving the 6-TG powder (sigma)
in 1N NaOH and ddH2O. 1000 × 6-TG was added to
DMEM and used at a final concentration of 15 mg/ml. 6-
TGmediumwas added 5 days after the I-SceI transfections.
HPRT-based I-SceI-cleavable reporter assay
The assay was based on human fibrosarcoma (HT1080)
cells with a functional but I-SceI-cleavable HPRT gene
(clone 5.2.1), as described previously (50). Use of this as-
say in conjunction with siRNA knockdowns has been pre-
viously described (51). Briefly, an I-SceI cut site was tar-
geted into exon 6 of the endogenous human HPRT gene,
without disrupting the functionality of the gene. These cells
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were seeded in 6-well plates and were immediately trans-
fected with siRNAs using RNAiMAX from Invitrogen ac-
cording to the manufacturer’s instructions. The following
day, medium was replaced with fresh DMEM. 48 h after
siRNA transfections, cells were lipofected with I-SceI plas-
mid, which was performed in a ratio of 6 g DNA: 18 l
Fugene in a total of 300l transfectionmix in DMEMwith
no Pen/Strep and fetal bovine serum to transfect each well
of a 6-well plate using the Fugene 6 transfection reagent
(Promega). 24 h later, medium was replaced with fresh
DMEM. Five days after the I-SceI transfection, the cells
were seeded in different densities within 100 mm plates (i.e.,
105, 5× 104, 104, and 103 per plate). Cells used to determine
the mutation frequencies were then exposed to 6-TG selec-
tion, while the cells used for determining plating efficien-
cies were kept in non-selective media. 6-TGmediumwas re-
freshed every 2–3 days. Cells were incubated for 10–12 days
to form colonies, which were stained and counted for the
purpose for calculating the mutation frequencies. Further,
a total of 30 clones from each genetic background were iso-
lated and grown in 48-well plates. These were subsequently
expanded into 24-well plates. At full confluency cells for
each clone were then trypsinised and collected for extrac-
tion of genomic DNA using a Qiagen Flexi gene DNA
kit according to the manufacturer’s instructions. Genomic
DNA was then quantified and used for PCR amplification
across the I-SceI break site and sequencing. Primers and
PCR conditions to amplify across the I-SceI site have been
previously described (51).
Data analysis
Sequence alignment was conducted using DNAData Bank
of Japan (DDBJ) ClustalW program (version 2.1).
Graphical display of results and statistical analysis
For all statistical analysis and graphical display, the pro-
gram GraphPad Prism (www.graphpad.com) was used.
siRNA transfections
HT1080 or U2OS or H1299 cells were transfected with
siRNAs (10 nM final concentration) using RNAiMAX
(Invitrogen) according to the manufacturer’s instructions.
Medium was replaced 24 h after transfection. The se-
quences of the siRNAs are listed below:
non-targeting (NT) proprietary sequence of supplier (Qi-
agen),
BRCA2 (Thermo Scientific): GGGAAACACUCAGA
UUAAAUU, UUUAAUCUGAGUGUUUCCCUU;
BRCA1 (Dharmacon): AAUGCCAAAGUAGCUAAU
GUAUUUU, AAUACAUUAGCUACUUUGGCAUUU
U;
CtIP (Dharmacon): GAGGUUAUAUUAAGGAAGA,
GGAGCUACCUCUAGUAUCA, GAACAGAAUAGG
ACUGAGU, GCACGUUGCCCAAAGAUUC;
MRE11 (Dharmacon): GGAGGUACGUCGUUUC
AGA, GGAAAUGAUACGUUUGUAA, CGAAAUGU
CACUACUAAGA, GAAAGGCUCUAUCGAAUGU;
RPA (Dharmacon): AACUGGUUGACGAAAGUG
GUGUU, CACCACUUUCGUCAACCAGUUUU;
POLQ (Ambion, Lifetechnologies): CCGCUUUUGG
AGUCAGUAATT, UUACUGACUCCAAAAGCGGT
A.
Western blotting
Whole cell extracts and the protein concentration measure-
ments for western blotting were performed as described
previously (51). Equal amounts of protein were separated
on NuPAGE Tris-Acetate or Bis-Tris gel (Invitrogen) and
transferred to a PVDF membrane (0.45 m pore size) (In-
vitrogen). After blocking, the membranes were incubated
with appropriate primary antibodies at 4◦C overnight fol-
lowed by secondary antibodies at room temperature for
1 h. Imaging of protein was performed by the BIO-RAD
ChemiDoc Imaging sytem.
Primary antibodies used for western blotting are listed
below:
BRCA2 (Santa Cruz, sc-28235); BRCA1 (Calbiochem,
OP92); RAD51 (Santa Cruz, sc-8349); CtIP (GeneTex
19E8); MRE11 (Abcam, ab33125); RPA32 (Abcam, 2175);
Tubulin (Sigma, T5168). All secondary antibodies were pur-
chased from Invitrogen.
Inhibitors
The PARP-1 inhibitor, Olaparib (AZD 2281) was dissolved
in DMSO and used at 5Mfinal concentration. TheDNA-
PKcs inhibitor, NU7441 (Axon) was dissolved in DMSO
and used at 5, and 15 M final concentrations.
Quantitative RT-PCR
RNA was extracted using an RNeasy mini kit (Qiagen).
A SuperScript R© VILOTM (Invitrogen/Life Technologies)
cDNA synthesis kit was used to reverse transcribe cDNA
from total RNA according to manufacturer’s instructions.
Quantitative PCR was performed using 7500 Fast Real-
Time PCR detection system (Applied Biosystems). Reac-
tions (25 l each) were prepared in triplicate in a 96-well
reaction plate. Each reaction contained 20 ng cDNA, 200
nM of each primer, 10 l water and 12.5 l Absolute Blue
QPCR SYBR lowROXMix (Thermo Scientific). DNA lev-
els were normalized to the GAPDH calculated using a 2-
Ct method. QPCR settings were as follows: Initializa-
tion at 95◦C for 15 min, denaturation at 95◦C for 15 s, an-
nealing at 60◦C for 30 s, and extension at 72◦C for 30 s and
repeat for 40 cycles. Primers used for the qRT-PCRare listed
below:
qRT-PCR F:5’-AGT CGC ACA CTG CTA CAG GAC
GA-3’
qRT-PCRR: 5’-GGCACAAAGGCATGTCGCATG
C-3’
GFP-based I-SceI-cleavable reporter assays (HR, C-NHEJ
and MMEJ)
To examine the effects of gene loss of function on the
HR, C-NHEJ, and MMEJ repair pathways a panel of
GFP-based I-SceI-cleavable reporter cell lines was used.
The cells were transfected with an I-SceI plasmid using
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Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions in 6-well plates 48 h after the siRNA
knockdowns. After 2 days, the cells from each well were
trypsinised and dispersed in 200 l medium. The 400 l
suspension was then immediately mixed with 200 l of 10%
formaldehyde, and vortexed for 2–3 s before FACS (FAC-
SCalibur) to quantitate the number of GFP positive cells.
For FACS analysis, non-overlapping gates were defined by
three populations of cells from the same cell line: normal
cells, cells transfected with EGFP or DsRed plasmids. 20
000 cells were analyzed for each sample.
RESULTS
BRCA2 depletion promotes DSB-induced deletions typical of
MMEJ
We have previously shown that siRNA-mediated depletions
of SETD2 or RAD51 had similar effects on I-SceI-induced
DSBs in the HPRT gene, namely an increased overall fre-
quency of HPRT mutagenesis associated with increases in
both deletion lengths and use of microhomologies on either
side of the deletions (51). These findings suggested a possi-
ble role for HR in suppressing MMEJ.
To test this further, we applied the same approach (Sup-
plementary Figure S1) to assess a possible role for other
HR factors in suppressing MMEJ. BRCA2, a key recom-
bination mediator in mammalian cells, facilitates RAD51
loading onto ssDNA.We therefore anticipated that BRCA2
might also suppress MMEJ. We first depleted BRCA2 and
measured the frequency of HPRT inactivation (mutation
frequency) following I-SceI-induced DSBs. Knockdown of
BRCA2 resulted in a significantly increased I-SceI-induced
mutation frequency (2.8%; P < 0.0001), compared to cells
treated with non-targeting control (NT) siRNA (1.1%)
(Figure 1A). Sequence analysis of HPRT-negative clones
derived from cells treated with NT siRNA (Figure 1B, and
Supplementary Figure S2A–C) or BRCA2 siRNA (Figure
1B, and Supplementary Figure S3) indicated average dele-
tion lengths of 5.6 and 49 bp, respectively. Thus BRCA2 de-
pletion resulted in a 9-fold increase in deletion lengths (P<
0.0001) (Figure 1C). Insertions at the HPRT break site were
also detected but their frequencies were not significantly al-
tered by BRCA2-depletion (Supplementary Figure S14).
Further examination of the sequences at deletion junc-
tions showed that the proportion of deletions appearing to
have arisen by MMEJ rose significantly from 43%, for cells
treated with NT control siRNA, to 72% for cells treated
with BRCA2 siRNA (P< 0.05) (Figure 1D). BRCA2 deple-
tion in HT1080 cells was confirmed by western blot (Fig-
ure 1E). To assess the effect of BRCA2 depletion on HR,
we used a previously described (51) U2OS cell line carry-
ing a well-characterized GFP-based reporter for HR (DR-
GFP) (52). We found that the frequency of HR in BRCA2-
depleted cells was significantly reduced by 41% compared
to the NT controls (P< 0.0001), consistent with a role for
BRCA2 in promoting HR (19) (Figure 1F). Thus BRCA2
depletion causes both a decrease in HR and an apparent
increase in MMEJ suggesting roles for BRCA2 not only in
promoting HR but also in suppressing MMEJ.
BRCA1 depletion promotes DSB-induced deletions typical of
MMEJ
BRCA1 is also an essential factor for HR but has a dis-
tinct function in HR compared to BRCA2, where BRCA1
facilitates 5′ to 3′ resection of DSBs to generate 3′ ssDNA
tails (56). To investigate a possible role for BRCA1 in sup-
pressing MMEJ, we examined the effect of BRCA1 deple-
tion on DSB mutational signatures in the HPRT reporter
system. Like BRCA2 depletion, BRCA1 depletion resulted
in a significantly enhanced mutation frequency (3.5%; P =
0.001) following I-SceI-induced DSBs compared to that of
NT controls (1.1%) (Figure 2A). Further, sequencing of in-
dividually isolated HPRT mutated clones from a BRCA1-
depleted background (Figure 2B and Supplementary Fig-
ure S4) indicated an average deletion length of 17 bp, sig-
nificantly (3-fold) greater than the deletion lengths in NT
control siRNA-treated cells (P = 0.04) (Figure 2C). Inter-
estingly, the deletion lengths in BRCA1-depleted cells were
significantly (2.8-fold) smaller than to those in BRCA2-
depleted cells (P < 0.05). This is consistent with the early
role for BRCA1 in promoting resection during HR, prior to
BRCA2-assisted RAD51 loading. Insertions at the HPRT
break site were also detected but their frequency was not
significantly altered by BRCA1-depletion (Supplementary
Figure S14). Among the sequenced junctions in HPRT neg-
ative cells, 66% (P< 0.05) appeared to have been generated
by MMEJ following BRCA1 depletion, a 1.5-fold increase
over the 43% in cells with normal BRCA1 levels (Figure
2D). Therefore, BRCA1 depletion, like BRCA2-depetion,
resulted in a significant increase in the proportion of mu-
tagenic NHEJ events appearing to occur by MMEJ (Fig-
ure 2D). BRCA1 depletion in HT1080 cells was confirmed
by western blot (Figure 2E). Consistent with the role of
BRCA1 in HR (14), HR was significantly reduced by 52%
(P < 0.0001) in the DR-GFP reporter (U2OS cells) (52)
following BRCA1 knockdown (Figure 2F). Thus, BRCA1
depletion results in reduced HR repair and significantly in-
creasedmutation frequency associatedwith a larger propor-
tion of MMEJ events. Together with the similar effects of
BRCA2, RAD51 and SETD2 depletion, these results sug-
gest a common role for HR factors in suppressing MMEJ.
MMEJ-like DSB repair in HR deficient cells is independent
of DNA-PKcs
Although the microhomologies we observed at repair junc-
tions in HR-defective cells were highly suggestive that
MMEJ is the key pathway involved, we wanted to test
the possible involvement of C-NHEJ. Because C-NHEJ,
but not MMEJ, is dependent on DNA-PKcs, we therefore,
compared theHPRTmutational profile following treatment
of cells with a DNA-PKcs inhibitor (NU7441), or siRNA
against RAD51 in the presence and absence of NU7441.
This inhibitor has previously been shown to disrupt the C-
NHEJ repair pathway (57).We found that treating cells with
NU7441 resulted in a significant increase in the deletion
length (16 bp, P= 0.015) and a significantly increased pres-
ence of microhomologies at the break sites (60%, P< 0.05)
compared to that of the NT background (Figure 3A–C and
Supplementary Figure S5). This is consistent with a role for
DNA-PKcs in conjunction with Ku in protecting DSB ends
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Figure 1. BRCA2 depletion promotes DSB-induced deletions typical of MMEJ. (A) Break-induced mutation frequency of HPRT reporter cells treated
with NT control siRNA (NT), and BRCA2 siRNA (siBRCA2). Error bars represent SEM from three independent experiments. ****P < 0.0001. (B)
Representative sequence alignments of the PCR products in NT control (NT), and BRCA2-depleted (siBRCA2) cells isolated from three independent
experiments (see also Supplementary Figures S1A, S2A–C and S3). I-SceI recognition sequence and terminal microhomologies at the break sites are
highlighted. (C) Average length of deletions (bp) in different genetic backgrounds. Each dot represents an independent clone. The lines represent mean and
SEM, **** P < 0.0001. (D) Frequency of MMEJ at mis-repaired junctions in HPRT deletion mutants isolated from cells treated with NT control siRNA
(NT) or BRCA2 siRNA (siBRCA2). P values calculated by statistical analysis “difference between proportions”, * P < 0.05. (E) Western blot showing
BRCA2 knockdown in HT1080 cells 48 h following siRNA transfection. (F) HR repair efficacy of DR-GFP reporter cells treated with NT control siRNA
(NT), and BRCA2 siRNA (siBRCA2), indicated by the percentage of GFP-positive cells. Error bars show SEM from three independent experiments, ****
P < 0.0001.
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Figure 2. BRCA1 depletion promotes DSB-induced deletions typical ofMMEJ. (A) Break-inducedmutation frequency of HPRT reporter cells treated with
NT control siRNA (NT), BRCA1 siRNA (siBRCA1). Error bars represent SEM from three independent experiments. *** P < 0.001. (B) Representative
sequence alignments of the PCR products in NT control (NT), and BRCA1-depleted (siBRCA1) cells from three independent experiments (see also
Supplementary Figures S1A, and S4). I-SceI recognition sequence and terminal microhomologies at the break sites are highlighted. (C) Average length of
deletions (bp) in different genetic backgrounds. Each dot represents an independent clone. The lines represent mean and SEM, *P < 0.05, ***P < 0.001.
(D) Frequency of MMEJ at mis-repaired junctions in HPRT deletion mutants isolated from cells treated with NT control siRNA (NT) or BRCA1 siRNA
(siBRCA1). P values calculated by statistical analysis “difference between proportions”, *P < 0.05. (E) Western blot showing BRCA1 knockdown in
HT1080 cells 48 h following siRNA transfection. (F) HR repair efficacy of DR-GFP reporter cells treated with NT control siRNA (NT), and BRCA1
siRNA (siBRCA1), indicated by the percentage of GFP-positive cells. Error bars show SEM from three independent experiments, **** P < 0.0001.
and thereby promoting C-NHEJ and counteractingMMEJ
(25,58). Further, we found that the RAD51-depleted mu-
tational pattern following DSB induction was largely un-
affected by the presence of the DNA-PKcs inhibitor. In
particular, similar deletion lengths and use of microho-
mologies at the HPRT break-sites were observed following
RAD51 depletion in the absence or presence of NU7441
(P >0.05) (Figure 3A–C, and Supplementary Figure S6).
No statistical difference was found between the MMEJ lev-
els in cells treated with NU7441, siRNA against RAD51
or siRNA against RAD51 in combination with NU7441
(Figure 3C). These observations suggested that the DSB
mutational signature in the absence of HR is largely inde-
pendent of DNA-PKcs, a core C-NHEJ factor. To confirm
this in another system, we used a well-defined GFP-based
MMEJ reporter integrated within a U2OS cell line (EJ2-
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Figure 3. MMEJ-like DSB repair in HR-deficient cells is independent of DNA-PKcs. (A) Representative sequence alignments of PCR products obtained
from HPRT negative cells treated with NT control siRNA (NT), a DNA-PKcs inhibitor (NU7441), siRNA against RAD51 (siRAD51) or siRNA against
RAD51 plus NU7441 (siR+NU7441), from three independent experiments (see also Supplementary Figures S1A, S5-S6). I-SceI recognition sequence and
terminal microhomologies at the break sites are highlighted. (B) Average length of deletions (bp) in different genetic backgrounds. Each dot represents an
independent clone. The lines represent mean and SEM, n.s., not significant, ** P< 0.01. (C) Frequency of MMEJ at mis-repaired junctions in HPRT dele-
tionmutants isolated from cells treated withNT control siRNA (NT), NU7441, RAD51 siRNA (siRAD51) or RAD51 andNU7441 (siRAD51+NU7441).
P values calculated by statistical analysis “difference between proportions”, *P < 0.05. (D) Schematic map of the EJ2-GFP reporter (53) to assess MMEJ
efficacy, where the I-SceI cut site is flanked by 8 nucleotide homologous sequences capable of bridging the I-SceI-induced DSB by MMEJ and thus restor-
ing a functional GFP cassette. (E) MMEJ repair efficacy of EJ2-GFP reporter cells treated with NT control siRNA (NT), BRCA2 siRNA (siBRCA2),
DNA-PKcs inhibitor (NU7441) or BRCA2 and DNA-PKcs co-depleted cells (siBRCA2+NU7441), indicated by the percentage of GFP-positive cells. Er-
ror bars show SEM from three independent experiments. *P < 0.05. (F) MMEJ repair efficacy of EJ2-GFP reporter cells treated with NT control siRNA
(NT), BRCA1 siRNA (siBRCA1), DNA-PKcs inhibitor (NU7441) or BRCA1 siRNA and DNA-PKcs (siBRCA1+NU7441), indicated by the percentage
of GFP-positive cells. Error bars show SEM from three independent experiments. *P < 0.05, ** P < 0.01.
 at Im
perial College London on July 8, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
5750 Nucleic Acids Research, 2016, Vol. 44, No. 12
GFP) (53) (Figure 3D). Knockdown of BRCA2 in this sys-
tem significantly increased the GFP-positive cells, indica-
tive of MMEJ repair, compared to the NT controls (1.95-
fold, P= 0.0105) (Figure 3E), confirming that BRCA2 sup-
presses MMEJ. Also, DNA-PKcs inhibition by NU7441 in
this reporter cell line significantly increased the MMEJ re-
pair events by 2.24-fold (P = 0.0129) (Figure 3E), consis-
tent with a well-established role for C-NHEJ factors in sup-
pressing MMEJ (42). Further, inhibition of DNA-PKcs by
NU7441 in BRCA2-depleted cells led to a slight increase
of the GFP-positive cells compared to that of BRCA2-
depleted cells (1.62-fold;P= 0.0523) or control cells treated
with NU7441 (1.4-fold; P>0.05) (Figure 3E). When we re-
peated these experiments using BRCA1 depletion in place
of BRCA2 depletion, we obtained very similar results (Fig-
ure 3F). These data obtained from the GFP reporter are
consistent with those from the HPRT assay; in neither sys-
tem did treatment with DNA-PKcs inhibitor impair the in-
crease in MMEJ resulting from depletion of an HR protein
suggesting that DNA-PKcs is dispensable for the induction
of MMEJ in the HR-deficient cells.
Finally, to confirm that NU7441 efficiently inhibits C-
NHEJ, we treated the previously described GFP-based C-
NHEJ reporter (IRES-TK-EGFP, H1299 cells) (54) (Sup-
plementary Figure S7A) with NU7441 and observed a
93.6% (P < 0.0001) fall in C-NHEJ (Supplementary Fig-
ure S7B). RAD51 depletion was confirmed by western blot
(Supplementary Figure S7C). Collectively these data sug-
gest that MMEJ in HR-impaired cells is independent of
DNA-PKcs, a key factor for the C-NHEJ pathway. Also,
the GFP-based reporter data suggest that BRCA2 and
BRCA1 suppress MMEJ.
DSB-induced mutation signatures in HR-deficient cells re-
quire MMEJ factors
The above evidence shows clearly that DSB mis-repaired
junctions with microhomologies typical of MMEJ are en-
hanced when HR is impaired, and that this effect is C-
NHEJ-independent.We nevertheless sought direct evidence
thatMMEJ is indeed the pathway responsible for these mu-
tational signatures. We therefore used the HPRT system to
examine the DSB-induced mutational signatures following
depletion of essential MMEJ factors. Given that HR and
MMEJ share the initial resection step via CtIP andMRE11
(8,59,60), we investigated the impact of depleting these fac-
tors on the DSB-induced mutational signature. CtIP and
MRE11 were depleted by siRNA-mediated knockdown in
the HPRT reporter cells and the mutational frequencies
following I-SceI-induced break were quantified. We found
that, similar to the depletion of RAD51, SETD2, BRCA2
and BRCA1, depletion of either CtIP or MRE11 resulted
in a significant increase in the I-SceI-induced mutation fre-
quency (3.5%; P = 0.0007; and 3.6%; P < 0.0001, respec-
tively) compared to 1.1% in NT controls (Figure 4A). The
mutational frequencies in these backgrounds were slightly
but significantly greater than those in BRCA2 depleted cells
(P<0.05), consistent with roles for CtIP, and MRE11 up-
stream of BRCA2 duringHR. Surprisingly, sequence analy-
sis ofHPRT-negative clones derived fromCtIP- orMRE11-
depleted cells identified a distinctmutational signature com-
pared to that of SETD2-, RAD51-, BRCA2- or BRCA1-
depleted cells (Figure 4B, and Supplementary Figures S8
and S9). This signature involved deletions with comparable
lengths to those in NT controls (mean 5.6 bp), in contrast
to the increased deletion lengths seen in BRCA2-depleted
cells (mean 49 bp; P < 0.0001, and P < 0.001, respectively)
(Figures 1C and 4C). Further analysis of the mis-repaired
junctions of HPRT-negative clones from these backgrounds
identified a significant decrease in the proportion of repair
junctions associated with microhomologies in both CtIP-
(13%; P < 0.05), and MRE11- (31%; P < 0.05) depleted
cells, compared to NT controls (43% Figure 4D), or to
BRCA2 72 (Figure 1D) and BRCA1-depleted cells (65%,
Figure 2D). In summary, depletion of CtIP or MRE11, es-
sential MMEJ factors that promote the initiation of resec-
tion, significantly reduced the proportion of DSB-induced
deletions that were associated with microhomologies, rel-
ative to the NT controls. This contrasts sharply with de-
pletion of the HR proteins SETD2, RAD51, BRCA2 or
BRCA1, which significantly enhanced the same proportion
(Figures 1D and 2D) (51).
To assess the effect of CtIP andMRE11 depletion onHR,
we knocked down CtIP and MRE11 in the DR-GFP re-
porter (U2OS cells) (52) and found that the frequency of
HRwas significantly reduced by 92% (P< 0.0001), and 71%
(P < 0.0001), respectively (Figure 4E). CtIP and MRE11
depletions were confirmed by western blot (Figure 4F). To-
gether, these findings are in accordance with roles for CtIP
and MRE11 in the initiation of resection during both HR
and MMEJ.
PARP-1 is also known to play a key role in MMEJ by
competing with Ku to bind DSBs, which in turn leads to
the recruitment of MRE11 and CtIP to trigger resection
(33,61). Consistent with this, Olaparib has recently been
shown to decrease the Alt-NHEJ levels in the MMEJ-GFP
reporter assay (62). Therefore, we treated the HR-proficient
HT1080 cells (HPRT reporter) with a PARP-1 inhibitor,
Olaparib (AZD2281) (63), and examined the DSB muta-
tional pattern. The effects of Olaparib were similar to those
of CtIP or MRE11 depletion. Thus Olaparib significantly
increased themutation frequency (2.6%;P= 0.0073; Figure
4A) compared to the 1.1% in NT controls, generating dele-
tion lengths (mean 7 bp) comparable to the controls (mean
5.6 bp;P> 0.05; Figure 4B andC), and significantly shorter
than deletion lengths in BRCA2-depleted HPRT mutants
(mean 49 bp; P = 0.0005). Similarly, HPRT mutants aris-
ing following DSB induction in cells treated with Olaparib
showed a significant reduction in the proportion of dele-
tion junctions associated with microhomologies (25%; P
<0.05) relative to NT controls (57%) (Figure 4B, D and
Supplementary Figure S10), Collectively, these results sug-
gest that microhomologies at DSB mis-repaired junctions
in the HPRT reporter do indeed originate from the MMEJ
repair machinery.
To confirm that the MMEJ-like signature in HR-
compromised cells arises from MMEJ, we aimed to see
whether knocking down a core MMEJ factor could abol-
ish the MMEJ signature in these cells. We therefore, co-
depleted BRCA1 and MRE11 in the HPRT system and
monitored the DSB mutational signature. Simultaneous
knockdown of BRCA1 and MRE11 resulted in a signifi-
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Figure 4. DSB-induced mutation signatures in HR-deficient cells require MMEJ factors. (A) Break-induced mutation frequency of HPRT reporter cells
treated with NT control siRNA (NT), CtIP siRNA (siCtIP), MRE11 siRNA (siMRE11) or PARP-1 inhibitor (Olaparib). Error bars represent SEM from
three independent experiments, n.s., not significant, **P < 0.01, ***P < 0.001, ****P < 0.0001. (B) Representative sequence alignments of the HPRT
negative PCR products in cells treated with NT control siRNA (NT), CtIP siRNA (siCtIP), MRE11 siRNA (siMRE11) or PARP-1 inhibitor (Olaparib),
from three independent experiments (see also Supplementary Figures S1A, S8–10). I-SceI recognition sequence and terminal microhomologies at the break
sites are highlighted. (C) Average deletion lengths (bp) in different genetic backgrounds. Each dot represents an independent clone. The lines represent mean
and SEM, ***P < 0.001, ****P < 0.0001. (D) Frequency of MMEJ at mis-repaired junctions in HPRT deletion mutants isolated from cells treated with
NT control siRNA (NT) or CtIP siRNA (siCtIP), MRE11 siRNA (siMRE11) or Olaparib. P values calculated by statistical analysis “difference between
proportions”, *P< 0.05. (E) HR repair efficacy of DR-GFP reporter cells treated with NT control siRNA (NT), CtIP siRNA (siCtIP), or MRE11 siRNA
(siMRE11), indicated by the percentage of GFP-positive cells. Error bars show SEM from three independent experiments. ****P < 0.0001. (F) Western
blot showing CtIP and MRE11 knockdowns 48 h following siRNA transfection.
cantly increased mutation frequency of 3.4% compared to
that of theNT background (1.1%,P= 0.0013) (Supplemen-
tary Figure S11A). This increased frequency of HPRT loss
is consistent with the roles for BRCA1 and MRE11 in pro-
moting DSB repair (14,15). Further, the MMEJ signature
was absent in cells co-depleted for BRCA1 and MRE11.
This was associated with deletion lengths comparable to
that of NT cells (mean 5.6 bp), and a significantly reduced
proportion of MMEJ (27%) compared to that of NT cells
(43%, P < 0.05) (see Supplementary Figures S11 and S12).
Together these data confirm that the MMEJ-like signature
in the absence of HR factors is arising from the MMEJ
pathway.
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RPA suppresses MMEJ
RPA is a heterotrimeric ssDNA binding protein with roles
inDNA replication, recombination andDSB repair, includ-
ing HR. RPA displacement by RAD51 is a critical step in
HR (18). In this regard, it has been previously shown in S.
cerevisiae that RPA antagonizes MMEJ (45). Therefore, to
test a possible role for RPA in repressing MMEJ repair in
human cells, we used the GFP-based reporter for MMEJ
repair (53) (Figure 3D). RPA knockdown (Figure 5C) re-
sulted in significantly enhanced MMEJ levels compared to
the NT controls (2.9-fold; P < 0.0001) (Figure 5A), sug-
gesting that human RPA also suppresses MMEJ. POLQ
has recently been identified as an MMEJ-promoting fac-
tor in mammalian cells (46,47). Thus siRNA knockdown
of POLQ was used as a control for the GFP-based MMEJ
reporter, which led to 94% reduction in POLQ gene expres-
sion levels, as evaluated by qRT-PCR (Figure 5B). This was
found to significantly reduce MMEJ repair by 58% (P =
0.0112), consistent with its role in the mammalian MMEJ
pathway (Figure 5A). Further, co-depletion of RPA and
POLQ in the GFP-based MMEJ reporter led to signifi-
cantly reduced levels of MMEJ compared to that of RPA-
depleted cells (P = 0.0007). Surprisingly, however, MMEJ
levels in cells co-depleted for POLQ and RPA were still
significantly greater than NT controls (P = 0.0022) (Fig-
ure 5A), suggestive of the possible existence of POLQ-
dependent and POLQ-independent MMEJ pathways be-
ing suppressed by RPA. Finally, to confirm the role for
POLQ in promoting MMEJ in the HPRT assay, we de-
pleted POLQ in this system and monitored the DSB muta-
tional pattern. Analysis of the mutational signature in cells
treated with siRNA against POLQ showed a significantly
decreased MMEJ levels compared to that of the NT back-
ground, (Figure 5D and E and Supplementary Figure S13).
These results resemble our findings in the MMEJ-GFP as-
say, confirming that the HPRT and theGFP reporter assays
measure the same process.
DISCUSSION
Mutations arising from aberrant DSB repair are deleterious
for cells and can give rise to genomic instability, a hallmark
of cancer (64). Yet how DSB-induced chromosomal rear-
rangements are suppressed is poorly characterized. Further,
there is little mechanistic insight into the relationship be-
tween disrupting repair pathways and the mechanisms of
DSBmis-repair. Here, using an I-SceI-cleavable reporter as-
say based on the human endogenous HPRT gene (50,51),
together with an array of I-SceI-cleavable GFP-based re-
porter assays (52–54), in different cancer cell lines we have
established a role for HR factors in suppressing mutagenic
MMEJ following DSB resection. In this context, we con-
sider MMEJ to arise as the default pathway following HR
inactivation rather than being actively suppressed by HR
(see model in Figure 6). Following on from our initial ob-
servations in RAD51- and SETD2-depleted cells (51), this
study confirms that depletion of other HR factors (BRCA2,
BRCA1 and RPA) also results in significantly elevated lev-
els of a common DSB mutational signature in which DSB-
induced deletions are associated with microhomologies of
2–6 bp at the break junctions. Our observations are in align-
ment with the recent studies in human cells indicating that
chromosomal rearrangement junctions formed by MMEJ
contain 2–6 bp ofmicrohomology regions (38). Further, our
data also indicate that while failed HR leads to an increase
in MMEJ-induced deletions, surprisingly no effect was ob-
served on insertions, suggesting that these arise through
other mutagenic NHEJ events in this context. In this re-
spect, insertions were still observed, albeit at low levels, fol-
lowing inhibition of DNA-PKcs or following knockdown
or inhibition of MMEJ factors, suggesting these insertions
arise through other end-joining mechanisms. However, this
needs to be investigated in more detail.
Because the junctional microhomologies can potentially
represent DSB mutational signatures of either C-NHEJ or
MMEJ pathways (65,66), it is important to know which
of these pathways is involved. However the abrogation of
these signatures following depletion or inhibition of CtIP,
MRE11, PARP-1, all of which facilitate MMEJ, provides
strong genetic evidence that the MMEJ pathway is respon-
sible. The observation that MMEJ levels are decreased fol-
lowing PARP-1 inhibition with Olaparib in the HPRT sys-
tem, is in agreement with a recent study in which a similar
finding was found using a GFP-based reporter assay (62).
Additionally, the persistence of junctional microhomolo-
gies in HR-depleted cells treated with DNA-PKcs in-
hibitor excludes the possibility that C-NHEJ is required.
These conclusions are further supported by the significantly
greater levels of MMEJ events detected by a GFP-based re-
porter following depletion of HR factors, even when DNA-
PKcs is inhibited (Figure 3E and F). Our findings there-
fore indicate that, following DSB induction, HR proteins
preserve genomic integrity by suppressing mutations aris-
ing through the MMEJ pathway. MMEJ can be considered
an important DSB repair pathway in its own right. How-
ever our data suggest that its levels can be increased as a
result of disrupted HR. In this respect, we know MMEJ
has been proposed to be higher during S/G2 (59), which
may arise through incomplete HR. For example, one-ended
breaks arising from replication collapse may give rise to
both MMEJ and HR.
While the role of CtIP and theMRNcomplex in resection
initiation is well established (67), the exact role of BRCA1
in resection remains uncertain (68–70). It has recently been
reported that, although the BRCA1-CtIP interaction is not
crucial for DNA end-resection, it enhances the speed of
CtIP-mediated resection (17). It is also known that CtIP
and MRE11 are required for both HR and MMEJ repair
pathways by triggering resection (59). Differing results re-
garding the contribution of BRCA1 in MMEJ have been
reported. Thus, while one recent study in MEFs found that
BRCA1 facilitatesMMEJ at uncapped telomeres (49), work
in DT40 (chicken) B cells suggested that MMEJ is not in-
fluenced by BRCA1 (70). Various studies of plasmid-based
(exogenous) DSB repair substrates in human cells, however,
provide evidence that BRCA1 represses Alt-NHEJ events
by promoting the fidelity of NHEJ. (48,71–73). Here, using
an endogenous HPRT assay together with GFP reporter
assays in different human cell lines, we identified a DSB-
induced mutational signature for BRCA1-depleted cells,
which is distinct from that of CtIP-depleted or MRE11-
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Figure 5. RPA suppresses MMEJ. (A) MMEJ repair efficacy of EJ2-GFP reporter cells treated with NT control siRNA (NT), POLQ siRNA (siPOLQ),
RPA siRNA (siRPA) and POLQ plus RPA (siPOLQ+siRPA) indicated by the percentage of GFP-positive cells. Error bars show SEM from three indepen-
dent experiments. **P < 0.01, ***P< 0.001, ****P < 0.0001. (B) POLQ gene expression measured by RT-qPCR using the primers indicated in Materials
andMethods. (C)Western blot showing RPA knockdown 48 h following siRNA transfection. (D) Representative sequence alignments of the PCR products
(see Supplementary Figure S13) in NT control (NT), and POLQ-depleted (siPOLQ) cells. I-SceI recognition sequence and terminal microhomologies at
the break sites are highlighted. (E) Frequency of MMEJ at mis-repaired junctions in HPRT deletion mutants isolated from cells treated with NT control
siRNA (NT) or POLQ siRNA (siPOLQ). P values calculated by statistical analysis “difference between proportions”, * P < 0.05.
depleted cells. The significantly greater HPRT deletion
lengths in BRCA1-depleted cells compared to those of CtIP
or MRE11-depleted cells supports the notion that BRCA1
operates downstream of CtIP and MRE11. Further, the
significantly smaller HPRT deletion lengths in BRCA1-
depleted cells compared to those of BRCA2-depleted cells,
suggests that BRCA1 functions downstream of CtIP and
MRE11 but upstream of BRCA2 during HR to promote
genome stability by facilitating resection and thereby sup-
pressing the mutagenic MMEJ. Moreover, the significantly
increased levels of MMEJ, detected by both the HPRT
and GFP assays, following BRCA1 depletion suggest that
BRCA1 suppresses MMEJ repair. This is in agreement
with previous studies using plasmid-based reporter systems
(48,71).
POLQ has recently been identified as a polymerase that
contributes to mammalianMMEJ by promoting DNA end
joining and microhomology annealing (37,38). Further, re-
cent studies have suggested that cancer cells with defec-
tive HR are dependent on POLQ-mediated MMEJ repair
(46,47). Moreover, POLQ is upregulated in a range of hu-
man cancers, and indicates a poor clinical prognosis, espe-
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Figure 6. Model. DSBs are mainly repaired by C-NHEJ, however upon resection initiation by CtIP and MRN complex repair occurs via HR pathway. If
HR is disrupted after initiation of resection, regions of microhomology on either side of the break will anneal, resulting in repair via the mutagenic MMEJ
pathway.
cially in breast tumours (74–76). In agreement with these
reports, our observations support a role for POLQ in fa-
cilitating MMEJ in human cancer cells. Also RPA has an
established role in repressing MMEJ in S. cerevisiae by re-
moving DNA secondary structures, which prevent RAD51
loading and therefore HR (45,77). Consistent with this, we
demonstrate a striking role for RPA in suppressing muta-
genic MMEJ in human cancer cells. This could reflect roles
for RPA in early HR, thereby suppressing MMEJ and/or
in binding ssDNA, thereby preventing spontaneousMMEJ,
as previously proposed in S. cerevisiae (45). Our data, how-
ever, also identify dramatically increased MMEJ levels in
cells following simultaneous depletion of POLQ and RPA.
This is indicative of a role forRPA in suppressingMMEJ in-
dependently of POLQ,which could be explained by the sug-
gested involvement of POLQ in a subset of Alt-NHEJ re-
pair pathways specifically leading to insertions (78,79). Our
results also suggest that there might be POLQ-dependent
and POLQ-independent MMEJ pathways in human can-
cer cells, both of which are suppressed by RPA. Our data
do not, however, exclude the possibility that the slight resid-
ual activity of POLQ following its siRNA-mediated knock-
down, may contribute to the great MMEJ levels in cells
co-depleted for RPA and POLQ. In this regard, a more in-
depth analysis is required.
While our data show thatMMEJ is enhancedwhenHR is
impaired, the nature of the corresponding decrease in other
forms of mutagenic NHEJ is less clear and could indicate
inhibition of indel-forming C-NHEJ or other Alt-NHEJ
events that are not dependent on junctional microhomolo-
gies (6). Further analyses are required to identify which
DSB repair pathways are affected.
Our combined observations support a model (Figure 6)
in which DSB repair in HR-proficient cells, results in a mu-
tational signature with a particular balance between dele-
tions with and without associated microhomologies. When
HR is impaired, however, this balance is channeled toward
deletions associated withmicrohomologies as a result of en-
hancedMMEJ.Mechanistically, we propose that, following
DSB induction and initiation of resection, the repair path-
way choice can switch from HR to MMEJ, depending on
the availability of HR downstream proteins. In the absence
of HR factors, HR is blocked, and the resected ends are
poor substrates for C-NHEJ. As a result, microhomologous
sequences present on ssDNA either side of the resected ends
anneal via the mutagenic MMEJ repair mechanism leading
tomicrohomology-mediated deletions. Also consistent with
our findings, a recent study using MEFs found increased
translocation levels following Rad54 deletion (44). RAD54
is a key HR factor promoting recombination through inter-
actions with RAD51 (80). Although there is no sequence-
based evidence for the use ofmicrohomologies in generating
translocation junctions, translocations were largely PARP-
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1- and Lig 3-dependent suggesting that they had arisen via
the MMEJ pathway (39,81).
Mutations in DNA DSB repair genes are common fea-
tures in different human cancer types. Among the DSB re-
pair pathways, MMEJ is necessarily mutagenic and is fre-
quently associated with genomic rearrangements (39,82).
Importantly, high-resolution sequencing studies have iden-
tified microhomologies as a prevalent mutational signature
at rearrangement breakpoints in several cancer types in-
cluding breast, colorectal and prostate adenocarcinomas
(83,84). Our observations therefore suggest that the micro-
homology mutational signature in different types of malig-
nancies may arise from failed HR at a stage after the ini-
tiation of resection. This mechanistic understanding of the
interplay betweenHR andMMEJ repair pathways could be
exploited to develop therapies for cancer patients deficient
in these DSB repair pathways.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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